Interventional Spine, Inc. announced FDA clearance of the 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device, indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
This device joins the Interventional Spine family of Opticage™ Expandable Interbody Fusion implants cleared in 4Q15, and can also be used with the company’s PerX360 System™.
Opticage can be implanted via posterior, transforaminal or lateral approach.Source: Interventional Spine, Inc.
Interventional Spine, Inc. announced FDA clearance of the 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device, indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
This device joins the Interventional Spine family of Opticage™ Expandable...
Interventional Spine, Inc. announced FDA clearance of the 80 Lumbar Lordotic Opticage™ Expandable Intervertebral Body Fusion Device, indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
This device joins the Interventional Spine family of Opticage™ Expandable Interbody Fusion implants cleared in 4Q15, and can also be used with the company’s PerX360 System™.
Opticage can be implanted via posterior, transforaminal or lateral approach.Source: Interventional Spine, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
